Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 12/20 | 0.41 |
| ▸ | RARB | P10826 | 5/20 | 0.40 |
| ▸ | RARG | P13631 | 5/20 | 0.40 |
| ▸ | RXRB | P28702 | 3/20 | 0.40 |
| ▸ | RXRG | P48443 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 4/20 | 0.39 |
| ▸ | HNF4A | P41235 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915745 | 0.80 | RXRA (0.45) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL7422927 | 0.74 | RXRA (0.70) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL8811420 | 0.74 | CYP3A4 (0.46) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL3982018 | 0.72 | RXRA (0.72) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL6915712 | 0.71 | RXRA (0.72) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL2788640 | 0.71 | CYP3A4 (0.70) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL7622797 | 0.70 | RXRA (0.55) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL6274241 | 0.70 | RXRA (0.53) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL8809523 | 0.70 | CYP3A4 (0.42) | CYP3A4CYP26A1RXRARARBRARG | |
| SCHEMBL24055312 | 0.69 | RXRA (0.67) | CYP3A4CYP26A1RXRARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | CYP3A4 514/4885CYP26A1 420/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.